Navigation Links
Monoclonal antibody Hb3: A marker for colon cancer progression or as a therapeutic target?
Date:4/30/2008

There are a number of researchers who are searching for useful tumor markers to indicate cure. Antigens are being applied as an effective target in clinical therapy. Hb3 is an anti-colorectal cancer monoclonal antibody produced in the researchers laboratory, and whose sensitivity and specificity are superior to that of anti-CEA. Previous results have showed that CA-Hb3 may be useful in the clinical diagnosis of colorectal cancer.

This study, carried out by a team led by Professor G. C. Li, is described in a research article that will be published on March 14, 2008, in the World Journal of Gastroenterology.

To comprehensively identify the proteins of the tumor-associated antigen Ca-Hb3 which is recognized by colorectal carcinoma monoclonal antibody Hb3, Ca-Hb3 was isolated by SDS-PAGE followed by digestion with trypsin. The trypsin peptides were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Applying bioinformatics to analyze the proteins which were identified by mass spectrometry, Ca-Hb3 was identified as CKAP4-similar protein by nano-HPLC tandem mass spectrometry analysis. The molecular weight of CKAP4-similar protein is 62.02 kDa, including one hydrophobic region, one transmembrane domain, five coiled coils, four glycosylation sites and forty-nine phosphorylation sites. CKAP4-similar protein has high homogeneity with Np63, and the characteristic expression of agrNp63 alpha that is considered a potential oncogene in the isoforms of p63 is similar to Ca-Hb3.

Np63 is an isoform of the p63 family. A number of studies have highlighted the oncogenic potential of agrNp63 alpha.agrNp63 alpha is overexpressed in several epithelial cancers, often as a result of gene amplification. The overexpression of an Np63 isoform in Rat 1A cells increases colony growth in soft agar and xenograft tumor formation in nude mice. It is hypothesized that agrNp63 alpha promotes survival and the maintenance of proliferative capacity in both epithelial stem cells and cancer cells.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product
2. Autisms origins: Mothers antibody production may affect fetal brain
3. Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
4. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
5. Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Antibody responses in patients with Lyme arthritis
8. ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
9. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
10. Antibody Helps Repair MS Nerve Damage
11. Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber ... Canada to provide its range of unique and advantaged protective solutions to ... that will provide bilingual customer service and marketing support. A new distribution center ...
(Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
Breaking Medicine Technology: